CAR-T cell therapy: Evolution
Timeline
The milestones from first idea to today
| Year | Milestone |
|---|---|
| 1989 | Gross, Waks and Eshhar publish the first chimeric antigen receptors [2] |
| 2010 | CTL019, later Kymriah, is first tested at Penn in adults with chronic lymphocytic leukaemia [4] |
| 2012 | The Children's Hospital of Philadelphia begins studying it in children with leukaemia; Penn and Novartis start a global collaboration [4] |
| 2017 | The FDA approves Kymriah on 30 August, the first CAR-T therapy [3]; a second follows that year [8] |
| 2025 | Seven CAR-T therapies are approved in the United States [1] |
as of 2026-11-11
Lineage
The technologies it came from and the ones that came from it
Came before it- mAb Monoclonal antibodies Monoclonal antibodies made it possible to choose a marker to aim at; the 1989 receptors gave T cells antibody-type specificity [2].
- rDNA Recombinant DNA (genetic engineering) Kymriah was the first therapy based on gene transfer approved by the FDA [4].
as of 2026-11-11
Sources
- CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers National Cancer Institute (NIH), 2025
- Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity Proceedings of the National Academy of Sciences (Gross, Waks, Eshhar), record at MIGAL, 1989
- FDA Approves Novartis' CAR-T Drug, First Gene Therapy Approval in US Pharmaceutical Technology, 2017
- FDA Approves Personalized Cellular Therapy for Advanced Leukemia (news release) Penn Medicine, 2017
- Cells as cancer drugs National Cancer Institute, Center for Cancer Research